gene

CERS2

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CERS2: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

208Connections

1Hypotheses

1Analyses

50Outgoing

50Incoming

4Experiments

2Debates

Summary

CERS2 (Ceramide Synthase 2, also known as Lass2) is a ceramide synthase enzyme that catalyzes the synthesis of C20-C22 ceramides, playing critical roles in sphingolipid metabolism, membrane composition, mitochondrial function, and neuronal health.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	CERS2
Full Name	Ceramide Synthase 2 (Lass2)
Aliases	Ceramide Synthase 2, also known as Lass2
Chromosome	1q42.2
Protein Type	Enzyme
Target Class	Enzyme
Function	CERS2 inhibitors would reduce the enzymatic synthesis of very long-chain ceramides by blocking the condensation of serine and palmitoyl-CoA, thereby decreasing ceramide-mediated neuroinflammation a...
Mechanism of Action	CERS2 inhibitors would reduce the enzymatic synthesis of very long-chain ceramides by blocking the condensation of serine and palmitoyl-CoA, thereby decreasing ceramide-mediated neuroinflammation and apoptosis implicated in neurodegenerative pathology. This modulation of the ceramide signaling cascade may provide neuroprotective effects in Alzheimer's disease and related neurodegenerative conditions.
Druggability	Low (0.28)
Clinical Stage	Phase II
Molecular Weight	44 kDa
Amino Acids	380 aa
Pathways	Effect
UniProt ID	H0YNU7
NCBI Gene ID	29956
Ensembl ID	ENSG00000156599
OMIM	606922
GeneCards	CERS2
Human Protein Atlas	CERS2
Associated Diseases	AD, Aging, AMI, ARDS, ARM, bladder cancer
Known Drugs/Compounds	fingolimod
Interactions	Actin, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID, AND, APOPTOSIS
SciDEX Target	View Target Profile (2 clinical trials)
SciDEX Hypotheses	Sphingolipid Metabolism Reprogramming
KG Connections	208 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: CERS2 — AlphaFold H0YNU7 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

CERS2 — Ceramide Synthase 2 (Lass2)

gene · 1604 words

→

CERS2 Protein (Ceramide Synthase 2)

protein · 2431 words

→

Pathway Diagram

flowchart TD
    CERS2["CERS2"] -->|"catalyzes"| ceramide["ceramide"]
    h_6657f7cd["h-6657f7cd"] -->|"therapeutic target"| CERS2["CERS2"]
    CERS2["CERS2"] -->|"activates"| unfolded_protein_response["unfolded protein response"]
    h_6657f7cd["h-6657f7cd"] -->|"targets"| CERS2["CERS2"]
    CERS2["CERS2"] -->|"associated with"| bladder_cancer["bladder cancer"]
    CERS2["CERS2"] -.->|"inhibits"| migration["migration"]
    CERS2["CERS2"] -->|"causes"| growth_arrest["growth arrest"]
    CERS2["CERS2"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
    CERS2["CERS2"] -->|"regulates"| Ms["Ms"]
    CERS2["CERS2"] -->|"regulates"| Inflammation["Inflammation"]
    CERS2["CERS2"] -->|"regulates"| Longevity["Longevity"]
    CERS2["CERS2"] -->|"regulates"| Aging["Aging"]
    style CERS2 fill:#4a1a6b,stroke:#333,color:#e0e0e0
    style ceramide fill:#006494,stroke:#333,color:#e0e0e0
    style h_6657f7cd fill:#006494,stroke:#333,color:#e0e0e0
    style unfolded_protein_response fill:#5d4400,stroke:#333,color:#e0e0e0
    style bladder_cancer fill:#ef5350,stroke:#333,color:#e0e0e0
    style migration fill:#5d4400,stroke:#333,color:#e0e0e0
    style growth_arrest fill:#006494,stroke:#333,color:#e0e0e0
    style Parkinson_s_disease fill:#ef5350,stroke:#333,color:#e0e0e0
    style Ms fill:#ef5350,stroke:#333,color:#e0e0e0
    style Inflammation fill:#ef5350,stroke:#333,color:#e0e0e0
    style Longevity fill:#ef5350,stroke:#333,color:#e0e0e0
    style Aging fill:#ef5350,stroke:#333,color:#e0e0e0

Outgoing (155)

Target	Relation	Type	Str
ceramide	associated_with	entity	0.90
DIHYDROCERAMIDES	associated_with	entity	0.85
unfolded protein response	participates_in	pathway	0.70
Parkinson's disease	associated_with	disease	0.70
growth arrest	causes	phenotype	0.70
bladder cancer	associated_with	disease	0.70
migration	inhibits	biological_process	0.70
Inflammation	associated_with	disease	0.65
ALS	activates	disease	0.65
Obesity	activates	disease	0.65
Diabetes	activates	disease	0.65
Fibrosis	activates	disease	0.65
Ms	causes	disease	0.65
Inflammation	causes	disease	0.65
Als	activates	disease	0.65
Alzheimer	activates	disease	0.65
Ms	regulates	disease	0.65
Longevity	regulates	disease	0.65
Aging	regulates	disease	0.65
Obesity	regulates	disease	0.65
Diabetes	regulates	disease	0.65
Inflammation	regulates	disease	0.65
Glioblastoma	therapeutic_target	disease	0.65
Cancer	therapeutic_target	disease	0.65
Tumor	associated_with	disease	0.65
hippocampus	expressed_in	brain_region	0.60
Lipid Metabolism	regulates	pathway	0.60
Sphingolipid	regulates	pathway	0.60
Lipid Metabolism	inhibits	pathway	0.60
Er Stress	associated_with	pathway	0.60
Sphingolipid	interacts_with	pathway	0.60
BCL-2	interacts_with	gene	0.60
Apoptosis	therapeutic_target	pathway	0.60
IL-10	associated_with	gene	0.60
EMP1	activates	gene	0.60
Stem Cell	inhibits	cell_type	0.60
Epithelial	inhibits	cell_type	0.60
PAQR4	regulates	gene	0.60
Tgf-Β	activates	pathway	0.60
Chemokine	expressed_in	protein	0.60
Cytokine	activates	protein	0.60
Il-1	associated_with	protein	0.60
Ras	regulates	protein	0.60
App	regulates	protein	0.60
Ras	therapeutic_target	protein	0.60
Fgf	activates	protein	0.60
Aβ	activates	protein	0.60
EMP1	interacts_with	gene	0.60
EMP1	associated_with	gene	0.60
lipid metabolism	participates_in	pathway	0.60

Incoming (53)

Source	Relation	Type	Str
PAQR4	mediates	gene	0.95
EMP1	interacts_with	entity	0.90
h-6657f7cd	targets	hypothesis	0.90
SGMS1	activates	gene	0.60
INFLAMMATION	regulates	gene	0.60
APOPTOSIS	therapeutic_target	gene	0.60
AND	interacts_with	gene	0.60
CANCER	therapeutic_target	gene	0.60
EMP1	activates	gene	0.60
REL	regulates	gene	0.60
REL	causes	gene	0.60
SGMS2	activates	gene	0.60
CERS6	activates	gene	0.60
ASAH1	activates	gene	0.60
AMYLOID	activates	gene	0.60
FGF	activates	gene	0.60
ALZHEIMER	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
fingolimod	regulates	compound	0.60
SPTLC1	associated_with	gene	0.60
fingolimod	activates	compound	0.60
GENES	activates	gene	0.60
AND	activates	gene	0.60
GBM	associated_with	gene	0.60
BCL2	interacts_with	gene	0.60
BCL2L13	interacts_with	gene	0.60
CERS6	interacts_with	gene	0.60
IL-10	associated_with	gene	0.60
AND	associated_with	gene	0.60
PAQR4	regulates	gene	0.60
AGING	regulates	gene	0.60
AND	regulates	gene	0.60
AUTOPHAGY	activates	gene	0.60
ROS	activates	gene	0.60
NLRP3	activates	gene	0.60
SPTLC1	therapeutic_target	gene	0.60
C1Q	activates	gene	0.55
FGF-2	activates	protein	0.50
AUTOPHAGY	co_discussed	gene	0.50
AQP4	debate_co_mention	gene	0.45
C1Q	debate_co_mention	gene	0.45
C1QA	debate_co_mention	gene	0.45
P2RX7	co_discussed	gene	0.40
NTN1	co_discussed	gene	0.40
HSPG2	co_discussed	gene	0.40
P2RY12	co_discussed	gene	0.40
AQP4	co_discussed	gene	0.40
EPHB4	co_discussed	gene	0.40
SMPD1	co_discussed	gene	0.40
C1QA	co_discussed	gene	0.40

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Sphingolipid Metabolism Reprogramming	0.663	neurodegeneration	4R-tau strain-specific spreading pattern

Mentioning Analyses (1)

Scientific analyses that reference this entity

4R-tau strain-specific spreading patterns in PSP vs CBD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.732

Experiments (4)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
CERS2 genetic deletion rescues IL-10 deficiency inflammation	validation	inflammatory bowel disease	0.850	0.00	IL-10/CERS2 double knockout mi	proposed	N/A
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Validation: Membrane-Nucleation in iPSC Neurons	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,730,000
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000

Related Papers (17)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
EMP1 safeguards hematopoietic stem cells by suppressing sphingolipid metabolism [PMID:40624017]	Li L, Lei Y, Li Y, Xie Y, Hui P, Zang X,	Nat Commun	2025	1
IL-10 constrains sphingolipid metabolism to limit inflammation. [PMID:38383790]	York AG, Skadow MH, Oh J, Qu R, Zhou QD,	Nature	2024	1
PAQR4 regulates adipocyte function and systemic metabolic health by mediating ce [PMID:38961186]	Zhu Q, Chen S, Funcke JB, Straub LG, Lin	Nat Metab	2024	1
Sirtuin 1 mediated ceramide metabolism regulates intestinal mechanical barrier f [PMID:41856194]	Ma X, Liu Q, Mai K, Zhang Y	Int J Biol Macromol	2026	0
Metabolic abnormalities and reprogramming in cats with naturally occurring hyper [PMID:39499136]	["Li Q", "Homilius M", "Achilles E", "Ma	ESC heart failure	2025	0
Reduced circulating sphingolipids and CERS2 activity are linked to T2D risk and [PMID:39792658]	Khan SR, Ye WW, Van JAD, Singh I, Rabiee	Science advances	2025	0
Very long-chain fatty acids drive 1-deoxySphingolipid toxicity. [PMID:41298489]	["Majcher A", "Karsai G", "Yusifov E", "	Nature communications	2025	0
A multi-omics approach identifies the key role of disorders of sphingolipid meta [PMID:39638825]	["Qu Y", "Ma D", "Wu T", "Wang H", "Tian	Scientific reports	2024	0
Disruption of adipocyte HIF-1α improves atherosclerosis through the inhibition o [PMID:35847503]	Wang P, Zeng G, Yan Y, Zhang SY, Dong Y,	Acta pharmaceutica Sinica. B	2022	0
Fumonisin B [PMID:35777715]	["Li M", "Liu S", "Tan L", "Luo Y", "Gao	Food and chemical toxicology :	2022	0
Omega-3 polyunsaturated fatty acids reverse the impact of western diets on regul [PMID:35985403]	["Camacho-Mu\u00f1oz D", "Niven J", "Kuc	Biochemical pharmacology	2022	0
Metabolic Reprogramming-A New Era How to Prevent and Treat Graft Versus Host Dis [PMID:33343357]	["Kumari R", "Palaniyandi S", "Hildebran	Frontiers in pharmacology	2020	0
Evolution to the rescue: using comparative genomics to understand long non-codin [PMID:27573374]	["Ulitsky I"]	Nature reviews. Genetics	2016	0
New insights into the organ-specific adverse effects of fumonisin B1: comparison [PMID:25155190]	["Loiseau N", "Polizzi A", "Dupuy A", "T	Archives of toxicology	2015	0
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Cl [PMID:25452455]	["Stoffel E", "Mangu P", "Gruber S", "Ha	Journal of clinical oncology :	2015	0
Ceramide synthase 4 deficiency in mice causes lipid alterations in sebum and res [PMID:24738593]	["Ebel P", "Imgrund S", "Vom Dorp K", "H	The Biochemical journal	2014	0
Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determine [PMID:23209295]	["Zhu Y", "Massen S", "Terenzio M", "Lan	The Journal of biological chem	2013	0

Debates (2)

Multi-agent debates referencing this entity

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 4 · Score: 0.69 · 2026-04-12

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 7 · Score: 0.91 · 2026-04-10

Related Research

Hypotheses and analyses mentioning CERS2 in their description or question text

No additional research found